L3VLUP
ProSign in

BNTX in the 13F filings

Biontech Se · CUSIP 09075V102

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023
Quarter end
30 Sep 2025
the date the book describes
Filed
15 Dec 2025
latest of these filings; the earliest 31 Oct 2025
Managers listing it
4
at least, of 95 tracked, among listed positions
Comparable managers
95
filed both Q2 2025 and Q3 2025; 4 listed it in both
Shares listed
17,184,934
combined, among listed positions
Reported value
$1.7bn
combined, at the quarter end

Among the 95 comparable managers: 2 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing BNTX in Q3 2025

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2025, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

4 of 4 holders

ActionFiling
Baillie Gifford & Co7,879,359$777m0.58%Trimmed-159,51331 Oct 2025 (the filing on sec.gov)
Fidelity (FMR LLC)5,453,480$538munder 0.1%Trimmed-2,705,53113 Nov 2025 (the filing on sec.gov)
Dodge & Cox3,647,091$360m0.19%Added+2,769,65413 Nov 2025 (the filing on sec.gov)
Hudson Bay Capital Management LP205,004$20m0.07%Added+55,00415 Dec 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2025 to Q3 2025, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
10 in Q3 2024 to 9 in Q2 2026

Tracked managers listing it, at least.

0510152020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
BNTX by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20201$1.2mn.a.n.a.
Q2 20205$881mn.a.n.a.
Q3 20204$504mn.a.n.a.
Q4 20203$142mn.a.n.a.
Q1 20214$993mn.a.n.a.
Q2 202110$3.9bnn.a.n.a.
Q3 202112$4.2bnn.a.n.a.
Q4 20219$3.1bnn.a.n.a.
Q1 202210$1.9bnn.a.n.a.
Q2 202211$1.8bnn.a.n.a.
Q3 20228$1.8bnn.a.n.a.
Q4 202213$2.3bnn.a.n.a.
Q1 20238$1.6bnn.a.n.a.
Q2 202310$1.2bnn.a.n.a.
Q3 20239$1.2bnn.a.n.a.
Q4 20239$1.1bn52
Q1 20247$975m54
Q2 20249$877m72
Q3 202410$2.0bn73
Q4 20248$2.0bn46
Q1 20259$1.6bn45
Q2 20256$1.9bn25
Q3 20254$1.7bn22
Q4 20258$1.2bn216
Q1 20266$528m1216
Q2 20269$1.3bn1510

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

BNTX and GILD →BNTX and AMGN →BNTX and ARGX →Choose a stock to compare with BNTX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own BNTX, latest filings →Back to the 13F Explorer →